Entyvio and Burns second degree - a phase IV clinical study of FDA data

Summary:

Burns second degree is reported as a side effect among people who take Entyvio (vedolizumab), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Sulfasalazine, and have Deep venous thrombosis.

The phase IV clinical study analyzes which people have Burns second degree when taking Entyvio. It is created by eHealthMe based on reports of 23,685 people who have side effects when taking Entyvio from the FDA, and is updated regularly.

What is Entyvio?

Entyvio has active ingredients of vedolizumab. It is often used in crohn's disease. eHealthMe is studying from 23,827 Entyvio users. Check the latest studies of Entyvio.

What is Burns second degree?

Burns second degree is found to be associated with 212 drugs and 351 conditions by eHealthMe. Check the latest studies of Burns second degree.

On Aug, 11, 2026

23,685 people reported to have side effects when taking Entyvio.
Among them, 50 people (0.21%) have Burns second degree.

Could Entyvio cause Burns second degree?

Among these 50 people:

How long have people been on Entyvio when they have Burns second degree? *

What is the gender of people who have Burns second degree when taking Entyvio? *

female: 48.89 %
male: 51.11 %

What is the age of people who have Burns second degree when taking Entyvio? *

What are other drugs people take besides Entyvio? *

What are other side effects people have besides Burns second degree? *

Fatigue (feeling of tiredness): 50 people, 100.00%
Abdominal Discomfort: 49 people, 98.00%
Hypopnea: 49 people, 98.00%
Haematochezia (passage of stools containing blood): 49 people, 98.00%
Gingival Pain (gum pain): 49 people, 98.00%
Fever: 49 people, 98.00%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 49 people, 98.00%
Drowsiness: 49 people, 98.00%
Dizziness: 49 people, 98.00%
Nightmares (unpleasant dreams): 49 people, 98.00%

What are the existing conditions these people have? *

Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 48 people, 96.00%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 48 people, 96.00%
Ill-Defined Disorder: 45 people, 90.00%
High Blood Pressure: 43 people, 86.00%
Gastritis (inflammation of stomach): 42 people, 84.00%
High Blood Cholesterol: 29 people, 58.00%
Dyscalculia (impaired ability to learn grade-appropriate mathematics): 22 people, 44.00%
Cardiac Failure Chronic: 20 people, 40.00%
Adverse Drug Reaction: 17 people, 34.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 6.00%

* Approximation only. Some reports may have incomplete information.

Do you take Entyvio and have Burns second degree?

- Check whether Burns second degree is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Entyvio:

Entyvio (23,827 reports)

Browse all side effects of Entyvio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Burns second degree:

Burns second degree (212 drugs)

Browse all the conditions that are associated with Burns second degree:

Burns second degree (351 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vedolizumab (the active ingredients of Entyvio) and Entyvio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.